

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 July 2022 (14.07.2022)



(10) International Publication Number
WO 2022/150785 A3

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *C40B 40/10* (2006.01)
- (21) **International Application Number:**
PCT/US2022/012038
- (22) **International Filing Date:**
11 January 2022 (11.01.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/136,120 11 January 2021 (11.01.2021) US
- (71) **Applicant:** **ADIMAB, LLC** [US/US]; 7 Lucent Drive, Lebanon, New Hampshire 03766 (US).
- (72) **Inventors:** **STEIN, Caitlin**; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). **PEJCHAL, Robert**; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). **MCCREARY, Julia**; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire

03766 (US). **BARLOW, Kyle**; c/o ADIMAB, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). **SIVASUBRAMANIAN, Arvind**; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). **BATTLES, Michael Benjamin**; c/o ADIMAB, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US).

(74) **Agent:** **TESKIN, Robin, L.** et al.; BAKER, DONELSON, BEARMAN, CALDWELL & BERKOWITZ, P.C., Intellectual Property Department, 901 K Street, NW, Suite 900, Washington, District of Columbia 20001 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) **Title:** VARIANT CH3 DOMAINS ENGINEERED FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME, AND METHODS OF MAKING THEREOF




FIG. 1A

(57) **Abstract:** Variant CH3 domain polypeptides are provided that preferentially form CH3-CH3 heterodimers over CH3-CH3 homodimers. Such variant CH3 domains can be used to promote desired Fc pairing, thus providing for efficient development of bispecific and multispecific antibodies as well as Fc fusions of different formats. Methods of producing bispecific antibodies using such variant CH3 domains and for producing libraries containing such variant CH3 domains are also provided.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

11 August 2022 (11.08.2022)